Brief: Brainstorm Cell Therapeutics Submits Special Protocol Assessment Request To FDA For Phase 3B Trial Of NurOwn In ALS
23/02/2024 11:01
Feb 23 (Reuters) - Brainstorm Cell Therapeutics Inc
BCLI.O :
* BRAINSTORM CELL THERAPEUTICS SUBMITS SPECIAL PROTOCOL
ASSESSMENT
(SPA) REQUEST TO FDA FOR PHASE 3B TRIAL OF NUROWN® IN ALS
* BRAINSTORM CELL THERAPEUTICS SUBMITS SPECIAL PROTOCOL
ASSESSMENT
(SPA) REQUEST TO FDA FOR PHASE 3B TRIAL OF NUROWN® IN ALS
* BRAINSTORM CELL THERAPEUTICS INC - RESPONSE IS EXPECTED
WITHIN
45 DAYS OF SUBMISSION
Source text for Eikon: ID:nPn3Bfq0ra
Further company coverage: BCLI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Brainstorm Cell Therapeutics
See all newsBrief: Brainstorm Appoints Former FDA Associate Commissioner Peter J. Pitts As Executive Chairman
Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview